First Patient Enrolled in AFFIRM-205, a Ph III Study of LAE002 (afuresertib) + Fulvestrant for Treatment of Breast Cancer
“As shown in the results of Phase Ib study, the median PFS of afuresertib plus fulvestrant was 7.3 months. This is a significant improvement compared to the PFS data of 3-4 months for fulvestrant monotherapy. This combination therapy also demonstrated a favorable safety profile and the potential efficacy of AKT inhibitors to treat breast cancer, especially patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2- locally advanced or metastatic breast cancer”, said Academician Binghe Xu, the lead investigator of the study. “While therapies for breast cancer are increasing, the treatment of drug resistance remains one of the clinical challenges. I am feeling excited about the coming Phase III study of afuresertib in breast cancer”.
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data